The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis

被引:38
作者
Campbell, Richard Charles John [1 ,2 ]
Batley, Michael [2 ]
Hammond, Anthony [2 ]
Ibrahim, Fowzia [1 ]
Kingsley, Gabrielle [1 ]
Scott, David L. [1 ]
机构
[1] Kings Coll London, Sch Med, Weston Educ Ctr, Dept Rheumatol, London SE5 9RJ, England
[2] Maidstone Hlth Author, Dept Rheumatol, Maidstone ME16 9QQ, Kent, England
关键词
Anti-TNF; DAS28; Disease modifying anti-rheumatic drugs; Fatigue; Rheumatoid arthritis; ANTITUMOR NECROSIS FACTOR; QUALITY-OF-LIFE; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; CONCOMITANT METHOTREXATE; INADEQUATE RESPONSE; FACTOR THERAPY; TRIAL; ADALIMUMAB; HEALTH;
D O I
10.1007/s10067-011-1887-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigate a range of clinical factors and anti-rheumatic treatments, for their degree of association with rheumatoid arthritis (RA) fatigue in 557 patients. A range of clinical measures concerning disability, pain and disease activity together with drug history were recorded as part of routine clinical visits. Fatigue was measured using the Functional Assessment of Chronic Illness Therapy (FACIT-F) questionnaire. Spearman's correlation (p<0.05) evaluated FACIT-F against the other clinical measures. Mean FACIT-F was compared between the treatment groups. Multivariate linear regression analysis investigated association between the clinical measures and FACIT-F in more detail. Correlation (p<0.05) with FACIT-F was the strongest for Health Assessment Questionnaire (HAQ) (r=-0.68), patient global (r=-0.64) and pain (r=-0.62) visual analogue scores. In multivariate models, DAS28, HAQ and pain explained variability in fatigue the best (R-2=0.54). Further analyses, looking at the sub components of DAS28, show that fatigue is mainly associated with tender joint counts and pain rather than swollen joint counts or erythrocyte sedimentation rate. RA fatigue levels were not significantly different between patients on no treatment, disease modifying anti-rheumatic drugs or biologics. Fatigue in established RA is not specifically influenced by the type of treatment used but is associated with tender joint counts, pain and disability. This finding is in contrast to recent trials in early RA that suggest biologics are better than traditional disease modifying anti-rheumatic drugs for fatigue. This difference in result may be because the origins of fatigue are not the same in early compared with established RA.
引用
收藏
页码:717 / 722
页数:6
相关论文
共 28 条
[1]  
BELZA BL, 1993, NURS RES, V42, P93
[2]  
Cella D, 2005, J RHEUMATOL, V32, P811
[3]   Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire [J].
Cella, David ;
Lai, Jin-Shei ;
Stone, Arthur .
SUPPORTIVE CARE IN CANCER, 2011, 19 (09) :1441-1450
[4]   Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].
Cohen, Stanley B. ;
Emery, Paul ;
Greenwald, Maria W. ;
Dougados, Maxime ;
Furie, Richard A. ;
Genovese, Mark C. ;
Keystone, Edward C. ;
Loveless, James E. ;
Burmester, Gerd-Ruediger ;
Cravets, Matthew W. ;
Hessey, Eva W. ;
Shaw, Timothy ;
Totoritis, Mark C. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806
[5]   Established rheumatoid arthritis [J].
Conaghan, PG ;
Green, MJ ;
Emery, P .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 1999, 13 (04) :561-575
[6]   The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial [J].
Emery, P ;
Fleischmann, R ;
Filipowicz-Sosnowska, A ;
Schechtman, J ;
Szczepanski, L ;
Kavanaugh, A ;
Racewicz, AJ ;
Van Vollenhoven, RF ;
Li, NF ;
Agarwal, S ;
Hessey, EW ;
Shaw, TM .
ARTHRITIS AND RHEUMATISM, 2006, 54 (05) :1390-1400
[7]  
Furst DE, 2003, J RHEUMATOL, V30, P2563
[8]   Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition [J].
Genovese, MC ;
Becker, J ;
Schiff, M ;
Luggen, M ;
Sherrer, Y ;
Kremer, J ;
Birbara, C ;
Box, J ;
Natarajan, K ;
Nuamah, I ;
Li, T ;
Aranda, R ;
Hagerty, DT ;
Dougados, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) :1114-1123
[9]  
Goekoop-Ruiterman YPM, 2005, ARTHRITIS RHEUM-US, V52, P3381, DOI [10.1002/art.21405, 10.1002/art.23364]
[10]   Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-α inhibitors in adults with rheumatoid arthritis [J].
Greenwood, M. C. ;
Rathi, J. ;
Hakim, A. J. ;
Scott, D. L. ;
Doyle, D. V. .
RHEUMATOLOGY, 2007, 46 (07) :1165-1167